Psyence Biomedical Ltd. Warrant
Psyence Biomedical Ltd. Warrant
Your view on PBMWW
Overview
What the company does, where it operates, and who runs it.
About Psyence Biomedical Ltd. Warrant
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jody Aufrichtig
- Headquarters
- 121 Richmond Street West, Toronto, ON, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jody Aufrichtig
- Headquarters
- 121 Richmond Street West, Toronto, ON, CA
Psyence Biomedical Ltd. focuses on developing psychedelic medications derived from botanical psilocybin. The company is also investigating the use of natural psilocybin to alleviate adjustment disorder in patients with incurable cancer who are undergoing palliative care.
Its primary product candidate, PEX010, is a capsule containing naturally sourced psilocybin, which is currently undergoing a Phase IIb clinical study. PEX010 aims to treat anxiety, depression, and related conditions such as post-traumatic stress disorder, stress, grief, and adjustment disorder, especially in a palliative care context.
Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial, examining PEX010's efficacy in psilocybin-assisted psychotherapy for adjustment disorder caused by incurable cancer. Headquartered in Toronto, Canada, the company operates as a subsidiary of Psyence Group Inc.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Psyence Biomedical Ltd. Warrant, and the rating behind it. PBMWW last traded at $0.03; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Psyence Biomedical Ltd. Warrant. Starting points for Psyence Biomedical Ltd. Warrant: beta 1.68 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Psyence Biomedical Ltd. Warrant. Psyence Biomedical Ltd. Warrant does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Psyence Biomedical Ltd. Warrant. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Psyence Biomedical Ltd. Warrant. Psyence Biomedical Ltd. Warrant has reported as a listed company since 2024. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Psyence Biomedical Ltd. Warrant valued side by side against its closest peers. Psyence Biomedical Ltd. Warrant is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Psyence Biomedical Ltd. Warrant, and how their positions are changing. At a $2,110 market value, institutional positions materially move Psyence Biomedical Ltd. Warrant's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Psyence Biomedical Ltd. Warrant executives and directors. Shares of Psyence Biomedical Ltd. Warrant have traded between $0.02 and $0.03 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Psyence Biomedical Ltd. Warrant. Psyence Biomedical Ltd. Warrant is a $2,110 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Psyence Biomedical Ltd. Warrant. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Psyence Biomedical Ltd. Warrant. Coverage tracks Psyence Biomedical Ltd. Warrant within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.